TNFRSF1A and neoplasm: A number of strategies have been tested in an attempt to dampen down the immunosuppressive effects of Tregs in TME (reviewed in [3]), such as Tregs depletion using anti-CD25 mAbs, targeting immune checkpoint proteins (e.g., OX40 [230]), selectively targeting cell signalling (e.g., PI3Kδ) in Tregs (phase I, NCT02646748) [231], etc. Amongst these, targeting OX40, a member of the tumour necrosis factor receptor (TNFR) family [232], has shown promising anti-tumour activity.